bodyType

customContents

entityId

entityUuid

articlePageQuery

filter

article

articleBaseAdvertisingInfoArticle

articleListArticle

articleSeoArticle

hooksArticleAcknowledgementGateOverlayArticle

hooksTrackPageViewArticle

hooksContentInterestArticle

articleLinkingDataContent

hooksAmpRedirectArticle

articleSchemaContent

liveArticle

advertZone

sentiment

contentLock

topics

types

sections

paywallTypes

createdDate

publishedDate

sponsorType

urlAlias

moreOnThisArticles

commentCount

authorLocations

authors

corrections

displaySlideShow

multimediaEmbed

printHeadline

seriesContainer

articleSpeeches

socialHeadline

headline

images

flag

firstTopic

glossary

flattenTypeIds

image

relatedLinks

relatedNewsletters

__typename

sponsor

pdfFiles

seriesReverseOrder

series

disableOffPlatformContent

published

updatedDate

summary

subHeadline

body

keywords

readingTime

customTimezone

liveContents

Agence France-Presse

What if a simple pill could help heal from Covid-19?
US pharmaceutical giants Merck and Pfizer have announced encouraging results for oral drugs, while an antidepressant has also shown promise in what could open up a new chapter in the fight against the pandemic.
What are these treatments?
They are pills taken orally as soon as the first symptoms of Covid-19 appear, to avoid serious forms of the illness, and therefore hospitalisation.
This form of treatment has been sought since the start of the global health crisis.
After months of research, Merck and Pfizer say they have reached that elusive goal.
Early October, Merck said it was seeking authorisation in the United States for its pill molnupiravir, and Pfizer followed suit on Friday with paxlovid.
They are both antivirals that act by reducing the virus’s ability to replicate, slowing down the disease.
Both companies say clinical trials showed a strong reduction in the risk of hospitalisation.
Those who consumed molnupiravir saw that risk diminish by 50 per cent and those who took paxlovid by nearly 90 per cent, although direct comparisons of these efficacy rates should be avoided because of the different study protocols.
An antidepressant which is already available to the public, fluvoxamine, has also shown encouraging results in preventing serious forms of Covid-19, according to a study published in October by Brazilian researchers in the Lancet Global Health journal.
Merck says coronavirus pill cuts deaths and hospitalisations by half
Why are they important?
If the efficacy of these drugs is confirmed, it will be a major step forward in the fight against Covid-19.
They would add to vaccines to bolster the world’s therapeutic arsenal against the virus.
Treatments already exist, mostly in the form of synthetic antibodies.
But these drugs, which usually target those who already have severe forms of the disease, are injected and therefore more difficult to administer.
A pill can be quickly prescribed to a patient who will then take it easily at home.
Merck and Pfizer’s treatments, which so far have not shown many side effects, would entail taking around 10 doses over five days.
“The success of these antivirals potentially marks a new era in our ability to prevent the severe consequences of Sars-CoV2 infection,” British virologist Stephen Griffin told the Science Media Center.


What limitations?
It is difficult so far to properly evaluate Merck and Pfizer’s treatments given both groups have only published statements and have not made the data of their clinical trials available.
French infectious diseases specialist Karine Lacombe warned in September that these types of announcements should be treated with “caution” until the studies can be scrutinised.
She pointed out that these treatments represent a “potentially enormous” market for pharmaceutical groups.
Nevertheless, some elements indicate that Merck and Pfizer are not making empty promises.
For one, they both stopped their clinical trials earlier than expected as the results were so strong, with the OK of independent monitoring committees.
Where fluvoxamine is concerned, the data is available but is not without criticism.
Several researchers have complained that the authors did not just limit themselves to evaluating the frequency of hospitalisation, but also assessed the frequency of prolonged emergency room stays.
This, they say, complicated the interpretation of data.
Pfizer in talks with 90 nations for its Covid-19 pill; Merck eyes China deal
When? And how much?
Merck’s molnupiravir has already been approved in the United Kingdom where health authorities on Thursday gave their green light to its use in patients at risk of developing a serious form of the illness, such as the elderly, obese people, or those suffering from diabetes.
US and EU health authorities are also urgently reviewing the drug.
The European Medicines Agency promised on Thursday to “accelerate” proceedings, without giving a firm date.
Several countries have already ordered stocks of molnupiravir, such as the US, with 1.7 million courses of the drug.
The US order gives an idea of the steep price of the drug.
It comes to US$1.2 billion, which equates to around US$700 for a five-day course.
As for Pfizer, while it has not outlined a price for paxlovid, it has promised it will be “affordable” and subject to a tiered pricing approach based on the income level of countries.


Hong Kong’s Peninsula Hotels sees ‘bleisure’ boom after pandemic curbs, CEO says

US could require US$15,000 bonds for some tourist, business visas

China’s Shenzhen, Guangzhou airports hit record highs, surpass pre-Covid passenger levels

Landmark US Chinatown survived Covid, anti-Asian violence – but tariffs pose new threat

Coronavirus pandemic

What are Covid-19 pills and why are they important in the fight against the virus?

Merck’s molnupiravir has already been approved in Britain. Photo: Merck/TNS

Pfizer says Covid-19 pill Paxlovid cuts hospitalisation and deaths by 89 per cent

Pfizer said it plans to submit interim trial results for its pill to the US FDA for emergency use authorisation. Photo: AP

Merck says experimental coronavirus pill cuts deaths and hospitalisations by half

An independent group of medical experts monitoring the Merck trial recommended stopping it early because the interim results were so strong. Photo: Merck & Co. via AP

An antiviral pill, molnupiravir, is being co-developed by Merck & Co. and Ridgeback Biotherapeutics and tested in phase 3 clinical trials to treat and prevent early covid infections. Results are expected within months. (Merck & Co./TNS)

(FILES) In this file photo taken on October 2, 2013, Pharmaceutical company Merck employees walk past a Merck sign in front of the company's building in Summit, New Jersey. - Merck said on October 1, 2021, it will seek authorization in the US for an oral drug for Covid-19, after the pill showed "compelling results" in a clinical trial. The experimental drug, molnupiravir, significantly reduced the risk of hospitalization or death when administered to high-risk patients early in the disease, Merck and its partner Ridgeback Biotherapeutics said in a statement. (Photo by Kena Betancur / GETTY IMAGES NORTH AMERICA / AFP)

News

World

United States & Canada

Coronavirus

Health & Medicine

Explainers & FAQs

Antiviral pills molnupiravir and paxlovid developed by US companies Merck and Pfizer have shown encouraging results in preventing serious forms of Covid-19
If the efficacy of these drugs is confirmed, they would add to vaccines to bolster the therapeutic arsenal against the virus


Antiviral pills molnupiravir and paxlovid developed by US companies Merck and Pfizer have shown encouraging results in preventing serious forms of Covid-19.


Coronavirus pandemic: All stories

Medicine

Pfizer

Provide background, definition and detail of a specific topic, helping the reader understand how something works or what has happened in the past.  (Eg. What is Nafta? US and Mexico are on the verge of revising trade deal.)


Explainer